Database

Startups

Main Industry
Health Care
Main Product/Service
EDEN BIOSIMILAR
Founded Year
2012
Unified Business No.
54151980
Status
Active
Number of Employees
0
Total Paid-in Capital
3,059,391,410 (NT$)
Location of Company
Taiwan , New Taipei City
Exit Status
Emerging Stock Exchange(2015)、Acquired(2022)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
Founded in 2012, Eden Biologics is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality and affordable biosimilar medicines to patients in need and a formidable CDMO player for global a



More ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

CALGENT BIOTECHNOLOGY CO., LTD.

Calgent’s drug pipeline includes several novel therapeutic candidates. Their lead asset, CAL056 (Hectinib), is an oral first‑in‑class HECT-domain E3 ubiquitin ligase inhibitor for the treatment of multiple myeloma, which has received Orphan Drug Designati

VitaeBiomedical Co., Ltd.

VITAE Biomedical offers a Urine‑based Lung Cancer ELISA Reagent Kit, which uses dual highly specific antibodies in a sandwich assay to detect lung cancer–associated proteins in urine. The test shows high sensitivity and specificity, is CE‑certified in the

AltruBio Taiwan Inc.

AltruBio’s lead drug candidates are PSGL-1 agonist antibodies serving as immune checkpoint enhancers: ALTB-168, their first-generation molecule, has demonstrated safety and efficacy in Phase 1 and Phase 2 trials; and the next-generation ALTB-268, a tetrav